8 results about "Myelofibrosis" patented technology

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

Disclosed in the present invention are a PIM kinase inhibitor as shown in general formula II, a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the preparation of a drug for preventing and / or treating indications related to a PIM signaling pathway. The compound of the present invention is an ideal PIM kinase inhibitor with a high activity, which can be used for treating and / or preventing diseases including autoimmune diseases and tumors, e.g., inflammatory bowel disease, hematologic malignancies such as acute myeloid leukemia, myelofibrosis and chronic lymphocytic leukemia, and solid tumors such as gastric cancer and prostate cancer.

The invention features methods of treating a transfusion dependent subject having myelofibrosis, a cytopenia associated with myelofibrosis, such as anemia, thrombocytopenia, or neutropenia, or receiving treatment with a cytopenia-associated myelofibrosis treatment by administering to the subject an activin receptor type II (ActRII) signaling inhibitor, optionally in combination with a cytopenia- associated myelofibrosis treatment. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.

The invention relates to a combined pharmaceutical composition of pyrrolo [2, 3-c] pyridone compounds and application of the combined pharmaceutical composition. Specifically, the invention relates to a combined pharmaceutical composition of a compound shown as a formula (I) and application of the combined pharmaceutical composition to treatment of myelofibrosis.

The application provides a compound with a structure shown in a general formula (I), a deuterium compound, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same and a use thereof. The compound provided by the application has a good PIM kinase inhibition effect, is a novel, high-activity and low-toxicity ideal PIM inhibitor, and can be used for treating and / or preventing diseases such as acute myeloid leukemia, myelofibrosis, chronic lymphocytic leukemia, blood tumors such as gastric cancer and prostate cancer, and solid tumors.